leisure time -WSS

leisure time

author：entertainment 2025-09-28 08:13:16 - browse：384

Electrocardiogram in the shape of the United States map — Adobe

The market for artificial intelligence in health care is about as transparent as a brick wall. New tools achieve impressive results in published studies. But it is often difficult to compare them head to head with similar products, or tell whether they will work on different kinds of patients.

A new company is promising to change that — if it can convince AI developers to expose their products to more rigorous testing.

Called Dandelion Health, the New York-based firm is launching a first-of-its-kind public service to evaluate AI products on independent data designed to root out weaknesses and reveal bias. The company said Wednesday its initial pilot program, to begin next month, will focus on testing algorithms that use electrocardiograms to predict heart conditions.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： The pink breast cancer awareness ribbon needs a redesign

WSS

Readout Newsletter: XBI biotech index, Akero Therapeutics

The pink breast cancer awareness ribbon needs a redesign

Physician subsidies by hospitals soar in wake of No Surprises Act

CDC recommends rationing of RSV shot due to shortages

Readout Newsletter: The latest from Bristol, Sarepta, and Novartis

FDA struggles to regulate food additives, sometimes for decades

Wikipedia

leisure time

hotspot

Novavax promises a turnaround & Lilly roils the obesity market

How climate

Heart attack and stroke risk calculators need revising

STAT Wunderkinds: Ruey Hu's digital tools for parsing research

Moonlake's readout produced a cash windfall. Risks remain

Physician subsidies by hospitals soar in wake of No Surprises Act

Sports medicine is finally prioritizing gender equality

Hospitals warn Medicare's drug payment fix is ‘unlawful’

Wildfire smoke exposes gaps in outdoor worker protections

Emergency medicine has repudiated 'excited delirium.' Now what?

focus

Senate panel to vote on hospitals, PBMs, prisoner care

Eli Lilly to pay $200M for Beam’s stake in gene

Studies point to risks of excluding people with obesity from drug trials

Eli Lilly expects to double planned employment in Boston center

Senate committee scrutinizes Medicare Advantage brokers

STAT Readout Newsletter: Today's biggest biotech updates

hotspot

focus

entertainment

explore